CXCR4 and the cancer microenvironment
Full thesis title
A Bioinformatic Investigation into the Role of the CXCR4 Chemokine Receptor in Cancer Progression and Metastasis: Expression, Prognosis, and Immune Infiltration
I used public cancer datasets to examine CXCR4 expression, survival associations and immune infiltration. I wanted to see whether its association with prognosis differed between tissues.
High CXCR4 expression in LUAD was associated with longer overall survival and greater CD8+ T-cell infiltration. Survival associations in BRCA and READ were not significant.
These are associations in public datasets. They do not establish causation.Research questions and hypotheses
I compared CXCR4 expression and survival associations across breast, lung and colorectal cancer datasets, then examined genomic changes and immune infiltration.
- Expression: Is CXCR4 mRNA expression higher in breast, lung and colorectal tumors than in normal tissue?
- Genomic changes: Can genomic amplification or mutations explain elevated CXCR4 expression, or might transcriptional and microenvironmental factors contribute?
- Survival: Does higher CXCR4 expression correlate with shorter overall survival in each cohort?
- Immune infiltration: Is CXCR4 expression associated with CD8+ T-cell infiltration in tissues with different survival associations?
Working hypotheses: I tested two hypotheses: CXCR4 overexpression mainly reflects transcriptional changes rather than amplification, and high expression is associated with poor prognosis, with that relationship varying by immune infiltration in the tumor microenvironment.
Bioinformatics method
I analyzed TCGA cohorts with GEPIA2, cBioPortal, Kaplan–Meier Plotter, TIMER2.0 and STRING.
Gene expression
I compared CXCR4 mRNA expression in BRCA, LUAD and COAD tumors with normal tissue data from TCGA and GTEx using GEPIA2. I used one-way ANOVA with Log2FC = 1 and p < 0.01 cutoffs.
Genomic changes
I queried breast, lung and colorectal TCGA Pan-Cancer Atlas cohorts in cBioPortal, comparing mutation frequency, deep deletions and copy-number status with mRNA expression.
Survival analysis
I analyzed overall survival in BRCA, LUAD and READ using Kaplan–Meier Plotter. The software selected optimal expression cutoffs and calculated log-rank p-values and hazard ratios (HR) with 95% confidence intervals.
Immune infiltration and interaction networks
I used TIMER2.0 to examine the Spearman correlation between CXCR4 expression and CD8+ T-cell infiltration across several estimation algorithms. I used STRING to explore protein interaction networks.
Data sources and platforms
Findings by cancer cohort
1. Higher expression in breast and colon tumors
In GEPIA2, CXCR4 mRNA expression was higher in BRCA and COAD tumors than in normal tissue (p < 0.01). The difference in LUAD was smaller and not statistically significant.
2. Amplification alone did not explain expression
CXCR4 mutations and copy-number amplifications were uncommon in the queried TCGA cohorts (<2%). Amplified samples generally had high expression, but many diploid tumors did too. Amplification alone therefore did not explain the expression pattern. Transcriptional regulation or microenvironmental factors, such as hypoxia-related HIF-1α signaling, may contribute; this study did not measure those mechanisms directly.
3. Longer survival associated with high CXCR4 in LUAD
CXCR4 expression was not significantly associated with overall survival in BRCA or READ (p > 0.05). In LUAD, higher expression was associated with longer overall survival (p = 0.007).
4. Positive correlation with CD8+ T-cell infiltration
Several TIMER2.0 algorithms found a positive correlation between CXCR4 expression and CD8+ T-cell infiltration in LUAD (Spearman rho > 0). Higher expression was associated with a microenvironment containing more immune cells. The analysis does not show whether CXCR4 caused the infiltration or the survival difference.
5. Predicted chemokine network associations
The STRING network linked CXCR4 with CXCL12, CCL5, CXCL10, CXCL13 and CD4. These are predicted functional associations; not every network edge represents a direct physical interaction.
Analysis figures
Method record and study files
The JSON file contains the method details. The links below lead to the study files I can share.
My contribution
I examined public cohorts using analysis platforms and interpreted expression, genomic alterations, survival and immune-infiltration results together.
- Expression
- GEPIA2 · BRCA / LUAD / COAD
- Survival
- Kaplan–Meier Plotter · BRCA / LUAD / READ
- Genomics
- cBioPortal · TCGA Pan-Cancer Atlas
- Immune infiltration
- TIMER2.0 · Spearman correlation
Limits of this record
Expression sample counts were transcribed from the available figure labels. Analysis dates, dataset versions, survival cohort sizes and the HR/confidence interval for the LUAD finding are absent from the current record. The single available survival plot has no cohort label and displays p = 0.42; it does not verify the reported LUAD p = 0.007 result. The JSON is not a complete reproduction package.
Limitations and interpretation
I used public datasets and computational estimates to study associations. Establishing biological cause and effect would require further work.
- No protein-level validation: I analyzed mRNA abundance. Protein amounts and receptor localization would need separate validation with methods such as immunohistochemistry or Western blotting.
- Estimated immune infiltration: TIMER2.0 estimates immune infiltration from bulk gene expression. It does not count cells directly or establish how they migrate.
- Automatically selected cutoffs: Kaplan–Meier Plotter selected expression cutoffs to separate survival groups. The association needs independent validation with a fixed cutoff, including prospective studies.
- Differences between datasets: TCGA and GTEx differ in data processing and sample composition. Batch effects, tumor stage and treatment history may affect the results.
References
- Chatterjee, S., Behnam Azad, B., & Nimmagadda, S. (2014). The intricate role of CXCR4 in cancer. Advances in Cancer Research, 124, 31–82. DOI: 10.1016/B978-0-12-411638-2.00002-1
- Domanska, U. M. et al. (2013). A review on CXCR4/CXCL12 axis in oncology: No place to hide. European Journal of Cancer, 49(1), 219–230. DOI: 10.1016/j.ejca.2012.05.005
- Furusato, B., Mohamed, A., Uhlén, M., & Rhim, J. S. (2010). CXCR4 and cancer. Pathology International, 60(7), 497–505. DOI: 10.1111/j.1440-1827.2010.02548.x
- Liu, K. et al. (2015). Expression of CXCR4 and non-small cell lung cancer prognosis: A meta-analysis. Int J Clin Exp Med, 8(5), 7435–7445. PMC: PMC4503038
- Luker, G. D. et al. (2021). At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 109(5), 969–989. DOI: 10.1002/JLB.2BT1018-715RR
- Minamiya, Y. et al. (2010). Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer, 68(3), 466–471. DOI: 10.1016/j.lungcan.2009.07.015
- Ottaiano, A. et al. (2021). Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis. Cancers, 13(13), 3284. DOI: 10.3390/cancers13133284
- Spano, J.-P. et al. (2004). Chemokine receptor CXCR4 and early-stage non-small cell lung cancer. Annals of Oncology, 15(4), 613–617. DOI: 10.1093/annonc/mdh136
- Wagner, P. L. et al. (2009). CXCL12 and CXCR4 in adenocarcinoma of the lung: Association with metastasis and survival. J Thorac Cardiovasc Surg, 137(3), 615–621. DOI: 10.1016/j.jtcvs.2008.07.039
- Wald, O. et al. (2006). CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. Journal of Immunology, 177(10), 6983–6990. DOI: 10.4049/jimmunol.177.10.6983
- Xu, C., Zhao, H., Chen, H., & Yao, Q. (2015). CXCR4 in breast cancer: Oncogenic role and therapeutic targeting. Drug Des Devel Ther, 9, 4953–4964. DOI: 10.2147/DDDT.S84932
- Zlotnik, A. (2008). New insights on the role of CXCR4 in cancer metastasis. The Journal of Pathology, 215(3), 211–213. DOI: 10.1002/path.2350